{
    "name": "amcinonide",
    "comment": "Rx",
    "other_names": [
        "Cyclocort"
    ],
    "classes": [
        "Corticosteroids",
        "Topical"
    ],
    "source": "https://reference.medscape.com/drug/amcinonide-topical-343514",
    "pregnancy": {
        "common": [
            "Pregnancy Category: C",
            "Lactation: It is not known whether topical administration of topical corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Use with caution."
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: It is not known whether topical administration of topical corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Use with caution."
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Underlying infection",
                "Hypersensitivity",
                "Use on groin, face, or axila",
                "Ophthalmic use"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Chronic therapy may interfere with growth and development in children",
                "Use med to very high potency for <2 wk to reduce local and systemic side effects",
                "Use low potency for chronic therapy",
                "Allergic contact dermatitis may occur",
                "Should not use occlusive dressings in presence of infection or weeping lesions",
                "Adrenal suppression may occur in younger patients or patients receiving high doses for prolonged periods",
                "Development of Kaposi's sarcoma with prolonged use reported (discontinue therapy if it occurs)",
                "Avoid medium to very high potency on face, folds, groin because can increase steroid absorption",
                "Use lower potency for peds (ie, increase BSA/kg, therefore increase systemic absorption)"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Skin atrophy",
            "percent": "2"
        },
        {
            "name": "Striae",
            "percent": null
        },
        {
            "name": "Burning",
            "percent": null
        },
        {
            "name": "Dryness",
            "percent": null
        },
        {
            "name": "Irritation",
            "percent": null
        },
        {
            "name": "Itching",
            "percent": null
        },
        {
            "name": "Hypertrichosis",
            "percent": null
        },
        {
            "name": "Acneform lesions",
            "percent": null
        },
        {
            "name": "Secondary infection",
            "percent": null
        },
        {
            "name": "Pigmentation changes",
            "percent": null
        },
        {
            "name": "HPA suppression",
            "percent": null
        },
        {
            "name": "with higher potency used",
            "percent": null
        },
        {
            "name": "wk",
            "percent": null
        }
    ]
}